GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2011

Tokai Raises $23M to Support Phase II Development of Prostate Cancer Drug

  • Prostate cancer therapeutics firm Tokai Pharmaceuticals raised $23 million in a Series D3 round of financing to support ongoing early clinical development of its lead candidate galeterone (TOK-001). Both the firm’s current investors, Novartis Venture Fund and Apple Tree Partners, participated in the fundraising.

    Galeterone is an orally administered, small molecule drug designed to disrupt growth and survival of prostate cancer cells. The firm says preclinical studies have shown the molecule has a three-pronged anticancer mechanism, acting as an androgen receptor antagonist, as a CYP17 lyase inhibitor, and also  by decreasing androgen receptor levels in prostate tumors.

    A Phase I proof-of-concept study with galeterone has been carried out as part of the Armor (androgen receptor modulation optimized for response) clinical development program for galeterone. The dose-ranging trial involved 49 patients with castration-resistant prostate cancer. It evaluated treatment-related safety and changes in prostate-specific antigen levels from baseline. Phase II studies are reportedly being planned.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

New NIH Budget Proposal Leaves Many Confused and Unsettled

Do you think that using the so-called “mandatory budget funds” to pay for the proposed $825 million increase, as well as $1 billion of the NIH’s existing budget is a good idea?

More »